Artificial intelligence is moving deeper into Canadian health care, with AI scribes becoming one of the fastest-growing tools in the sector. These systems can listen during a patient visit and help create notes for doctors. The main goal is simple: reduce the time doctors spend on paperwork and give them more time to focus on patients.
Demand for the technology has grown quickly. More than 10,000 health care providers signed up for a national program within two weeks. An independent review found that about 90% of clinicians saw value in the tools, while nearly 70% said the technology reduced their administrative work.
This rapid growth is also creating a new business market in Canada. Companies are developing AI tools for clinics and building systems that can connect with electronic health records. As more doctors use these tools, demand for software that can save time and improve daily work is likely to grow.
However, Canada faces a major challenge because its health care system is divided across provinces and territories. Each area can have different rules, standards and buying systems. This can make it difficult for technology companies to create one product that can be easily sold and used across the entire country.
The C.D. Howe Institute raised this issue on August 25. Its health group said Canada has strong AI research and valuable health data, but companies still face a system made up of many different rules and purchasing processes. These differences can slow the growth of health technology businesses.
Safety is another major concern. An audit found gaps in the use of some AI tools, while a review of 20 AI scribe products found errors in medical information. Some systems produced false details, while others left important parts out of patient notes. These findings show why doctors still need to check AI-generated records before using them.
The risks do not mean that AI scribes cannot be used in health care. Instead, they show the need for careful oversight and proper training. Doctors need to understand the limits of the technology and review the information it produces. AI should support medical professionals, rather than replace their judgment.
Patient privacy is also a key issue. AI scribes can handle highly private health information during medical visits, so health systems must ensure that this data is stored and used safely. Patients also need clear information about when AI is being used and how their information may be processed.
Canada Health Infoway has already supported a national AI scribe program. The program provided eligible primary care clinicians with funded access to approved AI scribe tools for one year. The initiative shows that there is strong interest among health care professionals and that the technology is moving beyond small pilot projects.
The growing demand could create opportunities for Canadian technology companies. Local firms could develop AI systems designed around Canada’s health care needs and rules. If these products prove successful at home, they could also have the potential to enter international markets.
Still, demand alone will not create a strong and trusted AI health market. Companies need clear rules, clinics need safe and reliable products, doctors need proper training, and patients need confidence that their private information is protected.
If those needs are met, AI scribes could become an important part of Canadian health care. They could reduce administrative work and give doctors more time with patients. At the same time, they could help create a growing Canadian technology sector focused on health care.
The business challenge is therefore clear. Canada needs to support useful artificial intelligence while maintaining strong safety, privacy and quality standards. The August 25 report puts this issue into focus as AI scribes move from early experiments toward wider use.
The next step will be to determine whether Canada can turn this growing demand into a safe, trusted and competitive homegrown AI industry. The technology is developing quickly, but its long-term success will depend on how well companies, health systems, doctors and regulators work together.
